In the last decade, treatment regimen including brentuximab vedotin have significantly improved prognosis for patients with CD30-expressing lymphomas...Here, we report preclinical data for the novel DuoBody®-CD3xCD30 (GEN3017), a CD3 bsAb targeting CD30-expressing tumor cells...CD30-expressing HL (L428) and ALCL (KI-JK) tumor cell lines were incubated with purified healthy donor T cells (E:T ratio = 4:1) and DuoBody-CD3xCD30 or bsIgG1-CD3xctrl for 72 hours. T-cell mediated cytotoxicity was measured by flow cytometry and expressed as the percentage viable tumor cells normalized to an untreated control sample.
2 years ago
Preclinical
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)